Boston Scientific (BSX) – Investment Analysts’ Recent Ratings Updates

Posted by Scott Moore on Feb 12th, 2025

A number of firms have modified their ratings and price targets on shares of Boston Scientific (NYSE: BSX) recently:

2/10/2025 – Boston Scientific had its price target raised by analysts at Barclays PLC from $111.00 to $118.00. They now have an “overweight” rating on the stock.
2/7/2025 – Boston Scientific had its price target raised by analysts at UBS Group AG from $105.00 to $130.00. They now have a “buy” rating on the stock.
2/6/2025 – Boston Scientific had its price target raised by analysts at Raymond James from $119.00 to $122.00. They now have a “strong-buy” rating on the stock.
2/6/2025 – Boston Scientific had its price target raised by analysts at Wells Fargo & Company from $100.00 to $118.00. They now have an “overweight” rating on the stock.
2/6/2025 – Boston Scientific had its price target raised by analysts at Morgan Stanley from $100.00 to $120.00. They now have an “overweight” rating on the stock.
2/6/2025 – Boston Scientific had its price target raised by analysts at Royal Bank of Canada from $105.00 to $116.00. They now have an “outperform” rating on the stock.
2/6/2025 – Boston Scientific had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
2/6/2025 – Boston Scientific had its price target raised by analysts at Stifel Nicolaus from $100.00 to $115.00. They now have a “buy” rating on the stock.
2/6/2025 – Boston Scientific had its price target raised by analysts at Citigroup Inc. from $107.00 to $122.00. They now have a “buy” rating on the stock.
2/3/2025 – Boston Scientific had its price target raised by analysts at Piper Sandler from $95.00 to $115.00. They now have an “overweight” rating on the stock.
1/31/2025 – Boston Scientific had its price target raised by analysts at Raymond James from $101.00 to $119.00. They now have a “strong-buy” rating on the stock.
1/29/2025 – Boston Scientific was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
1/10/2025 – Boston Scientific was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating. They now have a $108.00 price target on the stock.
12/18/2024 – Boston Scientific had its price target raised by analysts at Truist Financial Co. from $100.00 to $110.00. They now have a “buy” rating on the stock.
12/16/2024 – Boston Scientific had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $110.00. They now have an “overweight” rating on the stock.

Boston Scientific Stock Down 0.2 %

NYSE BSX traded down $0.18 during trading hours on Wednesday, hitting $105.80. 5,455,812 shares of the company traded hands, compared to its average volume of 6,163,806. The stock has a market capitalization of $155.93 billion, a price-to-earnings ratio of 84.64, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a twelve month low of $64.54 and a twelve month high of $107.17. The business’s 50-day moving average is $95.50 and its 200-day moving average is $87.72. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 6,528 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the transaction, the executive vice president now owns 26,449 shares in the company, valued at $2,776,351.53. This trade represents a 19.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,830 shares of company stock worth $5,149,969. 0.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider’s stock valued at $11,869,805,000 after purchasing an additional 1,600,062 shares in the last quarter. State Street Corp lifted its position in shares of Boston Scientific by 2.3% during the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider’s stock worth $5,266,522,000 after buying an additional 1,389,172 shares during the last quarter. Wellington Management Group LLP boosted its stake in Boston Scientific by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock valued at $3,230,293,000 after buying an additional 3,344,571 shares in the last quarter. Geode Capital Management LLC grew its position in Boston Scientific by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider’s stock valued at $2,729,371,000 after acquiring an additional 1,041,329 shares during the last quarter. Finally, Norges Bank acquired a new position in Boston Scientific during the fourth quarter worth about $1,762,522,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.